Clinical pharmacokinetics and pharmacological effects of carbamazepine and carbamazepine-10,11-epoxide. An update.
about
Impairment of carbamazepine-10, 11-epoxide elimination by valnoctamide, a valpromide isomer, in healthy subjects.The International College of Neuro-Psychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 2: Review, Grading of the Evidence, and a Precise AlgorithmPopulation pharmacokinetics of carbamazepine in Singapore epileptic patientsCrystallization of Carbamazepine in Proximity to Its Precursor Iminostilbene and a Silica SurfaceCarbamazepine-provoked hepatotoxicity and possible aetiopathological role of glutathione in the events. Retrospective review of old data and call for new investigation.Treatment of bipolar disorder: a systematic review of available data and clinical perspectives.The effect of poor compliance on the pharmacokinetics of carbamazepine and its epoxide metabolite using Monte Carlo simulationA hunt for the source of sepsis.Actions of zopiclone and carbamazepine, alone and in combination, on human skilled performance in laboratory and clinical tests.Monotherapy with conventional and controlled-release carbamazepine: a double-blind, double-dummy comparison in epileptic patientsThe effect of carbamazepine on valproic acid disposition in adult volunteers.Effect of valpromide on the pharmacokinetics of carbamazepine-10, 11-epoxide.Anticonvulsant Use in the Treatment of Bipolar Disorder: A Primer for Primary Care PhysiciansPolymorphic Variants of SCN1A and EPHX1 Influence Plasma Carbamazepine Concentration, Metabolism and Pharmacoresistance in a Population of Kosovar Albanian Epileptic PatientsStability-enhanced hot-melt extruded amorphous solid dispersions via combinations of Soluplus® and HPMCAS-HF.Treatment of bipolar disorder: a complex treatment for a multi-faceted disorder.Markedly Elevated Carbamazepine-10,11-epoxide/Carbamazepine Ratio in a Fatal Carbamazepine Ingestion.Practical considerations for carbamazepine use in bipolar disorder.Association of carbamazepine major metabolism and transport pathway gene polymorphisms and pharmacokinetics in patients with epilepsy.Chemical toxicology: reactive intermediates and their role in pharmacology and toxicology.Protein binding predictions in infantsCarbamazepine toxicity and poisoning. Incidence, clinical features and management.Factors influencing the fabrication of albumin-bound drug nanoparticles (ABDns): Part II. Albumin-bound carbamazepine nanoparticles (ABCns).Evaluation of cytochrome P450 inductions by anti-epileptic drug oxcarbazepine, 10-hydroxyoxcarbazepine, and carbamazepine using human hepatocytes and HepaRG cells.An audit of therapeutic drug monitoring of anticonvulsantsOptimization of hot melt extrusion parameters for sphericity and hardness of polymeric face-cut pelletsPrediction of drug-drug interactions with carbamazepine-10,11-epoxide using a new in vitro assay for epoxide hydrolase inhibition.Potential interaction between carbamazepine and loxapine: case report and retrospective review.Comparison of equations for predicting bound serum concentrations of carbamazepine and carbamazepine-10, 11-epoxide after polytherapy in patients with epilepsy.Inhibition by erythromycin of the conversion of carbamazepine to its active 10,11-epoxide metabolite.Single and multiple dose pharmacokinetics of tenidap sodium in healthy subjects.The effect of clobazam on steady state plasma concentrations of carbamazepine and its metabolites.Metabolism of 10,11-dihydro-10-hydroxyimino-5H-dibenz/b, f/azepine-5-carboxamide, a potent anti-epileptic drug.Neonatal cholestatic hepatitis from carbamazepine exposure during pregnancy and breast feeding.Elevation of carbamazepine-10,11-epoxide by quetiapine.Estimation and comparison of carbamazepine population pharmacokinetics using dried blood spot and plasma concentrations from people with epilepsy: the clinical implication.Plasma-exchange treatment for severe carbamazepine intoxication: a case study.Carbamazepine uptake into rat brain following intra-olfactory transport.In vitro characterization of carbamazepine-loaded precifac lipospheres.Synergic development of pharmacokinetics and bioanalytical methods as support of pharmaceutical research.
P2860
Q24541281-8EDD2BE4-58FB-4CF6-B4B2-294DB72E10A8Q28066714-4F32F253-3114-4384-B78A-6C26D92C3064Q28367563-8894E4C5-8A33-4FB1-8342-4DB2E2B2144AQ28833259-F2AF42C7-49CF-472B-94EF-0C1081047BD8Q30728586-A36F4D4F-C2B4-4D16-BF7F-7A7045797C73Q33364302-CF4E4E17-472D-4E29-B075-C67F084B6A7DQ33571434-6D0DCCF6-4DF0-4178-8DBB-C7048452BDAAQ33802230-3CD8486E-7EDE-409E-8360-8B48BF257FEDQ34357267-77B87E2B-04B3-4C38-AA8B-EF31977EE69DQ34358589-E43B9053-A7C2-4128-86AD-844519125F76Q34397409-A98F1BE8-45EB-49D7-9546-6A04A84C9DD5Q34417511-A6D3C260-EC4B-418A-B923-7ABC38A528F4Q35664266-C9136AB2-BEAF-4A4C-8C08-92B698121785Q35837256-950261EE-4C40-449A-9773-9C4EF6BB1756Q35868365-868CB5B9-929B-4D85-9C2D-E21C34D55C2DQ36162402-80375A95-7352-4D2F-AE44-987878EF8A9BQ36208919-A58C8B30-0A74-4545-B39E-F84A4D116C51Q36506812-410B49C6-57AD-4017-B35A-1B087F93CA39Q36603317-13456AFF-23A5-4979-BA5B-7A73C250360DQ36662875-C1879D34-BEF2-4313-8BBA-B282196E6DB5Q37361786-29C68F75-A344-410D-A457-7D50C92FC592Q38627226-F6F370C2-845C-4E5A-B294-ADEA1649C0C2Q38750708-C1F5108C-951E-4F13-8543-E83C59A47E6FQ38808413-DB4F3D04-0470-4825-8687-9B17D77B3201Q39806874-52F1A6E8-A5BF-455F-9112-40329ACB4FAAQ39849775-70EF6235-FFAD-4BD1-B928-2A63CF4CC089Q39952608-D77D584E-C5FD-47E6-8EEB-B928AF749DDFQ40785814-87B40F40-3C53-407C-8138-373F09938E7FQ40949599-57973EA0-59B2-408D-8AE2-D9F220D6A32EQ41772429-BBDB3548-5B4C-45AD-B50A-B0D98A2042CBQ42119667-BB1DC01F-7CA0-40D0-B2A2-B05DDE2DD8EAQ43222926-A474375D-BD26-4F5D-8B4D-8032CFD5367EQ43898837-4C260D76-50D4-45B0-8CDA-2D9A218A29D5Q43936429-1ADA5408-4B4D-42B5-9262-1E90C6A88CCAQ44217123-B26FB839-8346-453F-8C78-E8E522BD5AC0Q45348069-5EDACD76-E70C-4194-ACA5-052C820E9A15Q45348655-CE44D75F-F1BE-4C83-B5F2-D22A5876973BQ46879751-C55CBE8E-EA97-496F-AF1C-7904EBB98B07Q46901838-30E8DBDF-6467-4389-A611-B638A8833FA0Q50349770-B1EC2A28-BBF7-456A-830A-F5AD41A5191A
P2860
Clinical pharmacokinetics and pharmacological effects of carbamazepine and carbamazepine-10,11-epoxide. An update.
description
1986 nî lūn-bûn
@nan
1986年の論文
@ja
1986年学术文章
@wuu
1986年学术文章
@zh-cn
1986年学术文章
@zh-hans
1986年学术文章
@zh-my
1986年学术文章
@zh-sg
1986年學術文章
@yue
1986年學術文章
@zh
1986年學術文章
@zh-hant
name
Clinical pharmacokinetics and ...... pine-10,11-epoxide. An update.
@en
Clinical pharmacokinetics and ...... pine-10,11-epoxide. An update.
@nl
type
label
Clinical pharmacokinetics and ...... pine-10,11-epoxide. An update.
@en
Clinical pharmacokinetics and ...... pine-10,11-epoxide. An update.
@nl
prefLabel
Clinical pharmacokinetics and ...... pine-10,11-epoxide. An update.
@en
Clinical pharmacokinetics and ...... pine-10,11-epoxide. An update.
@nl
P1476
Clinical pharmacokinetics and ...... pine-10,11-epoxide. An update.
@en
P2093
L Bertilsson
P304
P356
10.2165/00003088-198611030-00001
P577
1986-05-01T00:00:00Z
P6179
1016642558